TY  - JOUR
AU  - Jaramillo, Sonia
AU  - Krisam, Johannes
AU  - Le Cornet, Lucian
AU  - Kratzmann, Markus
AU  - Baumann, Lukas
AU  - Eissymont, Olga
AU  - Crysandt, Martina
AU  - Görner, Martin
AU  - Kayser, Sabine
AU  - Krause, Stefan
AU  - Schliemann, Christoph
AU  - Gaska, Tobias
AU  - Kaufmann, Martin
AU  - Chemnitz, Jens
AU  - Schaich, Markus
AU  - Hoellein, Alexander
AU  - Platzbecker, Uwe
AU  - Kieser, Meinhard
AU  - Müller-Tidow, Carsten
AU  - Schlenk, Richard
TI  - Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
JO  - Haematologica
VL  - 109
IS  - 6
SN  - 0390-6078
CY  - Pavia
PB  - Ferrata Storti Foundation
M1  - DKFZ-2024-01199
SP  - 1973-1976
PY  - 2024
N1  - #LA:W010#
KW  - Humans
KW  - Gemtuzumab: therapeutic use
KW  - Gemtuzumab: administration & dosage
KW  - Leukemia, Myeloid, Acute: drug therapy
KW  - Leukemia, Myeloid, Acute: diagnosis
KW  - Antineoplastic Combined Chemotherapy Protocols: therapeutic use
KW  - Antineoplastic Combined Chemotherapy Protocols: adverse effects
KW  - Aminoglycosides: therapeutic use
KW  - Aminoglycosides: administration & dosage
KW  - Double-Blind Method
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Remission Induction
KW  - Aged
KW  - Induction Chemotherapy
KW  - Adult
KW  - Treatment Outcome
KW  - Benzimidazoles
KW  - Phenylurea Compounds
KW  - Gemtuzumab (NLM Chemicals)
KW  - Aminoglycosides (NLM Chemicals)
KW  - glasdegib (NLM Chemicals)
KW  - Benzimidazoles (NLM Chemicals)
KW  - Phenylurea Compounds (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:38385304
C2  - pmc:PMC11141665
DO  - DOI:10.3324/haematol.2023.284346
UR  - https://inrepo02.dkfz.de/record/290602
ER  -